### **AMENDMENTS TO THE CLAIMS**

Amend the claims as follows:

Claims 1-22. (Cancelled)

- 23. (new) A method for increasing the fusiogenic capacities of a gamete comprising contacting the gamete with a cyclic peptide comprising the tripeptide forming a binding site of fertilin beta to oocyte integrin.
- 24. (new) The method according to claim 23, wherein the tripeptide is X-(Q/D/E)-E, X being an amino acid.
- 25. (new) The method according to claim 24, wherein the tripeptide is FEE.
- 26. (new) The method according to claim 23, wherein said peptide has the following formula:

wherein X represents an amino acid, m and n are comprised between 0 and 14 and "TriPept" denotes said tripeptide.

### **BOMSEL** et al.

### U.S. National Phase of PCT/FR2004/002956

- 27. (new) The method according to claim 26, wherein m+n is less than 10, preferably less than or equal to 5.
- 28. (new) The method according to claim 27, wherein said peptide has the following formula:

# C-X- TriPept -C

wherein X is an amino acid.

- 29. (new) The method according to claim 28, wherein X is a small and uncharged amino acid or is selected in the group consisting of A, S or T.
- 30. (new) The method according to claim 23, wherein the cyclic peptide is in the form of a multimer.
- 31. (new) The method according to claim 23, wherein the gamete is an oocyte.
- 32. (new) The method according to claim 23, intended to improve in vitro fertilization.
- 33. (new) The method according to claim 23, intended to improve artificial insemination, and/or nuclear transfer in non-human animals.
- 34. (new) A cyclic peptide having the following formula:

# BOMSEL et al.

U.S. National Phase of PCT/FR2004/002956

wherein X represents an amino acid, m and n are comprised between 0 and 14, a variant or a derivative thereof.

- 35. (new) The cyclic peptide according to claim 34, wherein m+n is less than 10 or is less than or equal to 5.
- 36. (new) The cyclic peptide according to claim 35, wherein said peptide having the following formula:

where X is an amino acid or is selected in the group consisting of A, S or T.

- 37. (new) The cyclic peptide according to claim 36, wherein X is S.
- 38. (new) A multimer of cyclic peptides, said peptides having the following formula:

wherein X represents an amino acid, m and n are comprised between 0 and 14 and "TriPept" designates the tripeptide X-(Q/D/E)-E forming a binding site of fertilin beta to oocyte integrin.

#### BOMSEL et al.

### U.S. National Phase of PCT/FR2004/002956

- 39. (new) The multimer according to claim 38, wherein the tripeptide is FEE.
- 40. (new) The multimer according to claim 38, said peptide having the following formula:

## C-X- TriPept -C

wherein X is an amino acid or is selected in the group consisting of A, S or T.

- 41. (new) A composition intended for gamete culture comprising a peptide according to claim 34 or a multimer as defined above.
- 42. (new) A method for treating fertility problems comprising administering locally in a female genital tract a peptide according to claim 12 or a multimer as defined above.
- 43. (new) A method for screening compounds increasing the fusiogenic capacity of oocytes comprising 1) incubating the oocyte in the presence of the test compound; and 2) evaluating the ability of the compound to increase the fusiogenic capacity of the oocyte.
- 44. (new) The method according to claim 43, wherein the ability of the compound to increase the fusiogenic capacity of the oocyte is evaluated by at least one of the following criteria: binding to the oocyte, induction of adhesion protein displacement to

BOMSEL et al. U.S. National Phase of PCT/FR2004/002956

the oocyte surface (more particularly of integrin  $\alpha 6\beta 1$ ), fusion of the oocyte with a spermatozoon.